深圳市亦诺微医药科技有限公司 Immvira Co. Ltd Mediaroom

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVi...

2025-12-04 08:00 360

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders

SUZHOU, China, Sept. 9, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company") recently an...

2025-09-10 10:49 1043

ImmVira Announces First-in-Human Data of Engineered Exosome MVR-EX105 for Fat Reduction and Muscle Preservation by Topical Application at 2025 Annual Congress of the International Federation for the Surgery of Obesity and Metabolic Disorders

World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market

SUZHOU, China, July 28, 2025 /PRNewswire/ -- ImmVira Group ("ImmVira" or the "Company")recently ann...

2025-07-28 20:28 2513

World's First Engineered Exosome for Hair Growth & Localized Fat Reduction Secure INCI Designation: ImmVira Accelerates Access to Billion-Dollar Aging-related Market

ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

SUZHOU, China, June 10, 2025 /PRNewswire/ -- ImmVira, a global leading clinical-stage biotechnology...

2025-06-10 20:00 2141

ImmVira Announces First Patient Dosed in a Multi-Regional Phase II Clinical Trial Evaluating MVR-T3011 Oncolytic Immunotherapy in Patients with BCG-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting

SUZHOU, China, April 27, 2025 /PRNewswire/ -- From April 25 to April 30, 2025, U.S. time, ImmVira p...

2025-04-28 09:00 2104

ImmVira Presented Clinical Results of Oncolytic Product MVR-C5252 Targeting Malignant Glioma via Convection-Enhanced Delivery at 2025 AACR Annual Meeting

Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients

SUZHOU, China, April 10, 2025 /PRNewswire/ -- EonveLab, a subsidiary of ImmVira Group ("ImmVira," o...

2025-04-11 13:19 2972

Global First Engineered Exosome with INCI Name -- ImmVira Leads a New Era in International Cosmetic Ingredients

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for i...

2024-09-15 17:53 3837

ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients

ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

SHENZHEN, China, March 15, 2024 /PRNewswire/ -- ImmVira has recently announced that the U.S. Food a...

2024-03-15 13:56 2052

ImmVira's oncolytic product MVR-T3011 IT Intratumoral Injection Receives FDA Fast Track Designation for HNSCC Treatment

MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results

SHENZHEN, China, Nov. 9, 2023 /PRNewswire/ -- On November 9, 2023, ImmVira announced the successful...

2023-11-10 08:00 2367

MVR-T3011 IV, Global First Intravenous Oncolytic Product, Successfully Concludes Phase I Clinical Study in the U.S. with Outstanding Safety Results

ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

SHENZHEN, China, Aug. 22, 2023 /PRNewswire/ -- ImmVira announced to appoint Dr. Howard L. Kaufman a...

2023-08-23 10:51 2154

ImmVira Appoints Howard L. Kaufman, M.D. as Consulting Medical Advisor

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

SHENZHEN, China, June 6, 2023 /PRNewswire/ -- ImmVira submitted four abstracts covering latest resu...

2023-06-07 08:00 2813

ImmVira presented latest encouraging clinical results of two proprietary products at ASCO 2023

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

SHENZHEN, China, April 20, 2023 /PRNewswire/ -- On April 17, 2023, ImmVira announced the appointmen...

2023-04-21 09:06 2540

ImmVira Appoints Dr. Oliver Kong as Chief Medical Officer

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

SHENZHEN, China, April 17, 2023 /PRNewswire/ -- On April 18, 2023, U.S. time, ImmVira presented pre...

2023-04-19 08:29 2046

AACR 2023 | ImmVira presented preclinical study results of first CAR-T enabler oncolytic product MVR-T7011 at AACR Annual Meeting

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

SHENZHEN, China, March 29, 2023 /PRNewswire/ -- ImmVira announced that its oncolytic virus product ...

2023-03-30 08:00 2136

ImmVira's oncolytic product MVR-C5252 targeting malignant glioma obtained NMPA's approval for Clinical Trial in China

ImmVira Clinical Snapshot: Intratumoral Injected OV (MVR-T3011 IT) Monotherapy Achieved Median PFS of 12.9 Months on Treatment of Melanoma

SHENZHEN, China, Feb. 8, 2023 /PRNewswire/ -- ImmVira's first intratumoral injected OV product MVR-...

2023-02-09 08:00 2116

Latest News